Zevra Therapeutics Announces Interim Data From The Phase 2 Trial Of KP1077 For Idiopathic Hypersomnia, Showing SDX (API Of KP1077) Is Well-tolerated Across All Doses And Both Dosing Regimens Studied
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics has announced interim data from the Phase 2 trial of KP1077 for Idiopathic Hypersomnia, indicating that SDX (API of KP1077) is well-tolerated across all doses and both dosing regimens studied. Topline data from the completed trial is expected in the first half of 2024, with potential to initiate Phase 3 trial by the end of 2024.
October 02, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zevra Therapeutics' Phase 2 trial of KP1077 shows promising interim data, indicating potential positive impact on the company's stock in the short term.
The announcement of positive interim data from a Phase 2 trial is typically seen as a positive development for a pharmaceutical company, as it indicates progress in the drug development process. This could lead to increased investor confidence in the company, potentially driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100